News Column

New Stem Cells Study Findings Reported from Toronto Western Hospital (Stem cell therapy for the treatment of early stage avascular necrosis of the...

July 16, 2014



New Stem Cells Study Findings Reported from Toronto Western Hospital (Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news reporting out of Toronto, Canada, by NewsRx editors, research stated, "Avascular necrosis (AVN) of the femoral head (FH) is believed to be caused by a multitude of etiologic factors and is associated with significant morbidity in younger populations. Eventually, the disease progresses and results in FH collapse."

Our news journalists obtained a quote from the research from Toronto Western Hospital, "Thus, a focus on early disease management aimed at joint preservation by preventing or delaying progression is key. The use of stem cells (SC) for the treatment of AVN of the FH has been proposed. We undertook a systematic review of the medical literature examining the use of SC for the treatment of early stage (precollapse) AVN of the FH, in both pre-clinical and clinical studies. Data collected included: Pre-clinical studies - model of AVN, variety and dosage of SC, histologic and imaging analyses. Clinical studies - study design, classification and etiology of AVN, SC dosage and treatment protocol, incidence of disease progression, patient reported outcomes, volume of necrotic lesion and hip survivorship. In pre-clinical studies, the use of SC uniformly demonstrated improvements in osteogenesis and angiogenesis, yet source of implanted SC was variable. In clinical studies, groups treated with SC showed significant improvements in patient reported outcomes; however hip survivorship was not affected. Discrepancies regarding dose of SC, AVN etiology and disease severity were present."

According to the news editors, the research concluded: "Routine use of this treatment method will first require further research into dose and quality optimization as well as confirmed improvements in hip survivorship."

For more information on this research see: Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskeletal Disorders, 2014;15():1-10. BMC Musculoskeletal Disorders can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Musculoskeletal Disorders - www.biomedcentral.com/bmcmusculoskeletdisord/)

Our news journalists report that additional information may be obtained by contacting R.L. Lau, Toronto Western Hosp, Div Orthopaed Surg, Toronto, ON M5T 2S8, Canada. Additional authors for this research include A.V. Perruccio, H.M.K. Evans, S.R. Mahomed, N.N. Mahomed and R. Gandhi (see also Stem Cell Research).

Keywords for this news article include: Biotechnology, Canada, Toronto, Ontario, Cell Therapy, Biological Therapy, Stem Cell Research, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters